Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Abstract

The subject disclosure relates to compounds and compositions including chemotherapy agents and/or radiation therapy with bipolar trans carotenoids, and the use of such compounds for the treatment of various cancers including pancreatic and brain cancers.

1 - 24 . (canceled) 
     
     
         25 . A method of treating cancer in a human comprising:
 a) administering to the human trans sodium crocetinate and   b) administering to the human radiation therapy and chemotherapy,   wherein trans sodium crocetinate is administered 45-60 minutes prior to administration of the radiation therapy, the dose of trans sodium crocetinate is 0.15-0.35 mg/kg, and the chemotherapy is temozolomide.   
     
     
         26 . A method as in  claim 25 , wherein trans sodium crocetinate is administered at a dose of 0.25 mg/kg. 
     
     
         27 . A method as in  claim 25 , wherein said radiation therapy is external beam radiation therapy. 
     
     
         28 . A method as in  claim 25 , wherein said radiation therapy is administered 5 times per week for 6 weeks. 
     
     
         29 . A method as in  claim 25 , wherein temozolomide is administered 7 times per week for 6 weeks. 
     
     
         30 . A method as in  claim 25 , wherein said chemotherapy is administered after said radiation therapy. 
     
     
         31 . A method as in  claim 25 , wherein said cancer is brain cancer. 
     
     
         32 . A method as in  claim 31 , wherein said brain cancer is a glioblastoma multiforme. 
     
     
         33 . A method as in  claim 25 , wherein trans sodium crocetinate is in the form of a composition with a cyclodextrin. 
     
     
         34 . A method as in  claim 25 , wherein trans sodium crocetinate is in the form of a lyophilized composition with a cyclodextrin. 
     
     
         35 . A method of treating cancer in a human comprising:
 a) administering to the human trans sodium crocetinate and   b) administering to the human chemotherapy,   wherein trans sodium crocetinate is administered 30-120 minutes prior to administration of the chemotherapy, the dose of trans sodium crocetinate is 0.75-2.0 mg/kg, and the chemotherapy is one or more compounds selected from the group consisting of temozolomide, gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, nab-paclitaxel (albumin-bound paclitaxel), capecitabine, cisplatin, elotinib, paclitaxel, docetaxel, and irinotecan liposome.   
     
     
         36 . A method as in  claim 35 , wherein trans sodium crocetinate is administered 1-2 hours prior to administration of the chemotherapy. 
     
     
         37 . A method as in  claim 35 , wherein said cancer is a solid tumor. 
     
     
         38 . A method as in  claim 35 , wherein the cancer is selected from the group consisting of squamous cell carcinomas, melanomas, lymphomas, sarcomas, sarcoids, osteosarcomas, skin cancer, breast cancer, head and neck cancer, gynecological cancer, urological and male genital cancer, bladder cancer, prostate cancer, bone cancer, cancers of the endocrine glands, cancers of the alimentary canal, cancers of the major digestive glands/organs, CNS cancer, and lung cancer. 
     
     
         39 . A method as in  claim 35 , wherein the cancer is pancreatic cancer. 
     
     
         40 . A method as in  claim 35 , wherein trans sodium crocetinate is in the form of a composition with a cyclodextrin. 
     
     
         41 . A method as in  claim 35 , wherein trans sodium crocetinate is in the form of a lyophilized composition with a cyclodextrin.